Abstract Library

#4412 25-years of experience with somatostatin receptor-based therapy in patients with small intestinal neuroendocrine tumours

Introduction: Small intestinal neuroendocrine tumours are well-differentiated and express type 2 somatostatin receptors (SSTR2). Treatment with somatostatin analogues (SSA) (octreotide or lanreotide) has been a cornerstone in controlling tumour growth for 25 years. Peptide Receptor Radionuclide Therapy (PRRT), utilising radiolabelled SSA, was introduced in our institution in May 2009 as primarily 2nd line treatment after progression on SSA. The standard PRRT regimen includes 4 cycles of PRRT (7.4 GBq 177Lu-DOTATATE every eight weeks). Re-treatment protocols remain debated.

Conference:

Presenting Author: Andreassen M

Authors: Slott C, Oturai P, Langer S, Møller S, Hansen C,

Keywords: SSA, PRRT, small intestinal NET,

#4228 Evaluation of the impact of indoleamine 2,3-deoxygenase (IDO) enzyme activity in neuroendocrine tumors (NETs)

Introduction: Indoleamine 2,3-deoxygenase (IDO) enzyme, by inducing L-tryptophan (Trp) depletion and L-kynurenine (kyn) accumulation, contributes to the formation of an immunosuppressive microenvironment. Some studies highlighted that patient with cancer in treatment with immune checkpoint inhibitors (ICI) and with low Kyn/Trp values showed a better PFS and OS, but there are no data for NETs.

Conference:

Presenting Author: Mancini C

Authors: Mancini C, Mazzilli R, Zamponi V, Motta C, Salerno G,

Keywords: neuroendocrine tumor, IDO enzyme, Kyn/Trp ratio, immunotherapy,

#3994 Outlook for 615 small intestinal neuroendocrine tumor patients: Recurrence risk after surgery and disease-specific survival in advanced disease

Introduction: Small intestinal neuroendocrine tumors (siNET) are one of the most common neuroendocrine neoplasms. Radical surgery is the only curative treatment.

Conference:

Presenting Author: Andreassen M

Authors: Slott C, Langer S, Møller S, Krogh J, Klose M,

Keywords: Small intestinal neuroendocrine tumor survival, prognosis, recurrence,

#3992 Recurrence free survival and disease-specific survival in patients with pancreatic neuroendocrine neoplasms: A single center retrospective study of 413 patients

Introduction: The prognosis and impact of different prognostic factors in pancreatic neuroendocrine neoplasms (pNEN) remains controversial.

Conference:

Presenting Author: Andreassen M

Authors: Møller S, Langer S, Slott C, Krogh J, Palnæs Hansen C,

Keywords: Pancreatic neuroendocrine neoplasms incidence, clinical presentation, prognosis,

#3807 Key device attributes for Somatostatin Receptor Ligand (SRL) therapy in patients with neuroendocrine tumors (NETs)

Introduction: SRL injection effectiveness, safety and adherence are similar for independent vs healthcare setting administration, but patient preferences and satisfaction with devices vary. For other injectable hormones, device ease of use has been associated with more favourable outcomes. Elucidating preferred SRL device features should help HCPs decide which device best fits individual needs.

Conference:

Presenting Author: Martin W

Authors: Martin W, Kolarova T, Marks M, Follin C, de Herder W,

Keywords: NET, neuroendocrine tumor, somatostatin receptor ligands, SRL, device, preference,